Argenx shares rise 2.41% premarket after positive topline results from ADAPT SERON study.

Argenx SE rose 2.41% in premarket trading, driven by positive topline results from the pivotal ADAPT SERON study of VYVGART®. The study met its primary endpoint, demonstrating statistically significant and clinically meaningful improvements in MG-ADL total score for AChR-Ab seronegative gMG patients. Argenx plans to submit an sBLA to the U.S. FDA for label expansion to include adult AChR-Ab seronegative gMG patients across all three subtypes.